"NeoStem, Inc., a leader in the emerging cellular therapy industry, today announced results of a pooled analysis indicating that Melapuldencel-T, an investigational patient-specific immunotherapy for metastatic melanoma, may increase survival rates significantly for patients at the most advanced stages of the disease. The findings will be presented on Sunday, June 1 in a poster by Robert O. Dillman, MD, study author and Vice-President, NeoStem Oncology, at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago."

Editor's note: This is a press release from a company that manufactures an immunotherapy treatment for melanoma. The treatment, called Melapuldencel-T, is meant to boost a patient's own immune system to fight cancer. A recent study testing Melapuldencel-T in patients found promising results for the treatment.